Mark A. Kay - 16 Nov 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role
Director
Signature
/s/ Frederic Chereau, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Nov 2022
Net transactions value
$0
Form type
4
Filing time
17 Nov 2022, 20:14:47 UTC
Previous filing
21 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LOGC Common Stock Disposed to Issuer -784,557 -100% 0 16 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Stock Option (right to buy) Disposed to Issuer -140,615 -100% 0 16 Nov 2022 Common Stock 140,615 $0.7300 Direct F2, F3
transaction LOGC Stock Option (right to buy) Disposed to Issuer -13,089 -100% 0 16 Nov 2022 Common Stock 13,089 $0.7300 Direct F3, F4
transaction LOGC Stock Option (right to buy) Disposed to Issuer -12,500 -100% 0 16 Nov 2022 Common Stock 12,500 $0.3800 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mark A. Kay is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.
F2 The options vested upon grant on November 2, 2017.
F3 At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
F4 The options were fully vested as of January 31, 2022.
F5 The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.